Abvc Biopharma (ABVC) Profit After Tax (2010 - 2026)

Abvc Biopharma (ABVC) has 16 years of Profit After Tax data on file, last reported at -$1.6 million in Q1 2026.

• Quarterly Profit After Tax fell 65.25% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 183.64% YoY) and the FY2025 annual result came in at -$7.9 million, down 49.58% from the prior year.
• Profit After Tax rose to -$1.6 million in Q1 2026, from -$2.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$207515.0 in Q4 2023 to a low of -$6.1 million in Q1 2022.
• A 5-year average of -$2.3 million and a median of -$2.0 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax surged 95.52% — and 2025, when it tumbled 451.5%.
• Tracing ABVC's Profit After Tax over 5 years: stood at -$4.6 million in 2022, then surged by 95.52% to -$207515.0 in 2023, then plunged by 283.84% to -$796527.0 in 2024, then sank by 242.12% to -$2.7 million in 2025, then soared by 42.74% to -$1.6 million in 2026.
• The last three Profit After Tax figures came in at -$1.6 million (Q1 2026), -$2.7 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.